After completing this activity, pharmacists should be able to:
- discuss treatment options for hormone therapy;
- evaluate recent evidence on the risk/benefit ratio of hormone therapy;
- recommend preparations associated with the least risk of breast cancer and thromboembolism.
The 2016 Competency Standards addressed by this activity include: 1.5, 1.6, 2.2, 2.4, 3.1, 3.2, 3.3
Accreditation number: CX19067 Accreditation expires: 1/11/2021
This activity has been accredited for 1.0 hour of Group One CPD (or 1.0 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan, which may be converted to 1.0 hour of Group Two CPD (or 2.0 CPD credits) upon successful completion of the associated assessment activity.